Trapidil
 | |
| Clinical data | |
|---|---|
| Trade names | Rocornal, Avantrin, Travisco |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.035.834 |
| Chemical and physical data | |
| Formula | C10H15N5 |
| Molar mass | 205.265 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Trapidil is used in the treatment of chronic stable angina pectoris. It is currently marketed in Japan under the brand name Rocornal.[1]
An analog was assigned the codename AR 12-456.[2]
Pharmacology
[edit]Based on cell free in vitro activity assays, trapidil at therapeutic concentrations causes selective phosphorylation of cellular proteins through positive modulation of regulatory subunit RII(α/β) containing protein kinase A (PKA).[3][4] At higher, non-physiologically relevant concentrations, which are generally not achieved after administration of therapeutic doses, non-selective inhibition of phosphodiesterases occurs.[4] Further, the previous documented activities as an antagonist of platelet-derived growth factor[5] are abolished when a PKA inhibitor is administered, suggesting that these noted activities are PKA mediated.[4] At these higher concentrations,[6] additional effects have been noted including vasodilation and inhibition of platelet aggregation[7][8]
References
[edit]- ^ "ロコルナール錠100mg | 持田製薬株式会社". med.mochida.co.jp. Retrieved 2025-10-09.
- ^ Hering S, Bodewei R, Schubert B, Krause EG, Wollenberger A (1985). "Trapidil and other 5-triazolo-(1, 5-alpha)-pyrimidine derivatives as calcium channel blockers in 108CC5 cells". Biomedica Biochimica Acta. 44 (5): K37 – K41. PMID 2415119.
- ^ Sichelschmidt OJ, Hahnefeld C, Hohlfeld T, Herberg FW, Schrör K (June 2003). "Trapidil protects ischemic hearts from reperfusion injury by stimulating PKAII activity". Cardiovascular Research. 58 (3): 602–610. doi:10.1016/S0008-6363(03)00261-X. PMID 12798433.
- ^ a b c Bönisch D, Weber AA, Wittpoth M, Osinski M, Schrör K (August 1998). "Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase A". Molecular Pharmacology. 54 (2): 241–248. doi:10.1124/mol.54.2.241. PMID 9687564.
- ^ Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, et al. (December 1994). "Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica". Circulation. 90 (6): 2710–2715. doi:10.1161/01.cir.90.6.2710. PMID 7994812.
- ^ "Trapidil Professional Information (Summary of Product Characteristics/SPC)". Federal Institute for Drugs and Medical Devices (German). January 2019. Retrieved October 9, 2025.
- ^ Büyükafşar K, Yazar A, Düşmez D, Oztürk H, Polat G, Levent A (October 2001). "Effect of trapidil, an antiplatelet and vasodilator agent on gentamicin-induced nephrotoxicity in rats". Pharmacological Research. 44 (4): 321–328. doi:10.1006/phrs.2001.0864. PMID 11592868.
- ^ Liu M, Sun Q, Wang Q, Wang X, Lin P, Yang M, et al. (March–April 2014). "Effect of trapidil in myocardial ischemia-reperfusion injury in rabbit". Indian Journal of Pharmacology. 46 (2): 207–210. doi:10.4103/0253-7613.129320. PMC 3987192. PMID 24741195.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |